Latest Ratios: P/E Ratio 28.1x · EV/EBITDA 8.9x · ROE 4.2%. (2007–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $143M | $233M | $89M | $245M | $299M | $1.1B | $462M | $137M | $130M | $46M | $24M |
| Enterprise Value | $145M | $236M | $109M | $268M | $281M | $1.0B | $452M | $119M | $121M | $41M | $17M |
| P/E Ratio → | 28.15 | 45.41 | — | — | — | 2902.34 | — | — | 574.35 | — | — |
| P/S Ratio | 1.30 | 2.13 | 0.97 | 3.43 | 4.78 | 17.93 | 10.67 | 5.59 | 6.14 | 3.81 | 3.10 |
| P/B Ratio | 1.13 | 1.82 | 0.76 | 1.94 | 2.37 | 8.36 | 9.25 | 3.06 | 7.05 | 7.44 | 3.08 |
| P/FCF | 7.64 | 12.48 | 18.61 | — | 28.70 | 4577.39 | — | — | 185.50 | — | — |
| P/OCF | 7.62 | 12.45 | 18.18 | — | 28.04 | 1513.36 | — | — | 164.20 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.15 | 1.18 | 3.75 | 4.50 | 16.55 | 10.43 | 4.85 | 5.72 | 3.39 | 2.20 |
| EV / EBITDA | 8.87 | 14.38 | — | — | — | 436.03 | — | — | 244.09 | — | — |
| EV / EBIT | 12.05 | 19.25 | — | — | — | 2683.04 | — | — | 153.87 | — | — |
| EV / FCF | — | 12.63 | 22.76 | — | 26.98 | 4225.97 | — | — | 172.80 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.3% | 63.3% | 64.5% | 60.0% | 62.4% | 58.1% | 55.7% | 62.8% | 57.6% | 49.1% | 56.0% |
| Operating Margin | 11.0% | 11.0% | -14.9% | -36.9% | -19.7% | 0.6% | -4.9% | -15.0% | 0.8% | -17.6% | -20.4% |
| Net Profit Margin | 4.7% | 4.7% | -21.8% | -24.6% | -18.3% | 0.6% | -5.1% | -12.8% | 1.1% | -17.3% | -19.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.2% | 4.2% | -16.5% | -13.9% | -8.9% | 0.4% | -4.7% | -9.9% | 1.8% | -30.0% | -18.4% |
| ROA | 2.9% | 2.9% | -11.3% | -11.0% | -8.3% | 0.4% | -3.8% | -7.7% | 1.3% | -19.8% | -12.9% |
| ROIC | 6.8% | 6.8% | -7.2% | -15.4% | -11.9% | 0.6% | -4.8% | -15.3% | 2.5% | -170.4% | -156.8% |
| ROCE | 7.8% | 7.8% | -8.6% | -18.1% | -9.5% | 0.4% | -4.2% | -10.4% | 1.3% | -30.4% | -18.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.20 | 0.28 | 0.29 | 0.00 | 0.00 | 0.01 | 0.01 | — | — | — |
| Debt / EBITDA | 1.59 | 1.59 | — | — | — | 0.14 | — | — | — | — | — |
| Net Debt / Equity | — | 0.02 | 0.17 | 0.18 | -0.14 | -0.64 | -0.20 | -0.41 | -0.48 | -0.82 | -0.90 |
| Net Debt / EBITDA | 0.17 | 0.17 | — | — | — | -36.26 | — | — | -17.95 | — | — |
| Debt / FCF | — | 0.15 | 4.15 | — | -1.73 | -351.42 | — | — | -12.71 | — | — |
| Interest Coverage | 2.31 | 2.31 | -2.15 | -16.31 | — | — | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.04 | 3.04 | 2.89 | 3.04 | 11.74 | 12.29 | 3.28 | 4.44 | 3.77 | 2.49 | 2.78 |
| Quick Ratio | 3.04 | 3.04 | 2.89 | 3.04 | 11.74 | 12.29 | 3.28 | 4.44 | 3.77 | 2.49 | 2.78 |
| Cash Ratio | 1.10 | 1.10 | 0.72 | 0.77 | 8.83 | 9.04 | 1.05 | 3.09 | 2.11 | 1.45 | 1.92 |
| Asset Turnover | — | 0.62 | 0.54 | 0.39 | 0.46 | 0.43 | 0.72 | 0.43 | 0.85 | 1.24 | 0.68 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 128.43 | 151.39 | 190.30 | 129.49 | 147.69 | 150.72 | 110.07 | 111.15 | 103.26 | 144.11 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.6% | 2.2% | — | — | — | 0.0% | — | — | 0.2% | — | — |
| FCF Yield | 13.1% | 8.0% | 5.4% | — | 3.5% | 0.0% | — | — | 0.5% | — | — |
| Buyback Yield | 0.0% | 0.0% | 1.0% | 3.1% | 6.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.8% | 3.4% |
| Total Shareholder Yield | 0.0% | 0.0% | 1.0% | 3.1% | 6.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.8% | 3.4% |
| Shares Outstanding | — | $19M | $18M | $17M | $18M | $18M | $15M | $13M | $12M | $10M | $10M |
Includes 30+ ratios · 19 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OPRX stock.
OptimizeRx Corp.'s current P/E ratio is 28.1x. The historical average is 45.4x.
OptimizeRx Corp.'s current EV/EBITDA is 8.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 49.8x.
OptimizeRx Corp.'s return on equity (ROE) is 4.2%. The historical average is -58.8%.
Based on historical data, OptimizeRx Corp. is trading at a P/E of 28.1x. Compare with industry peers and growth rates for a complete picture.
OptimizeRx Corp. has 63.3% gross margin and 11.0% operating margin. Operating margin between 10-20% is typical for established companies.
OptimizeRx Corp.'s Debt/EBITDA ratio is 1.6x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
EHR partner dependency risk
Metrics are mathematically derived from official filings.
Market Pricing Reflects Execution Skepticism
As reported in recent financial data, OPRX trades at an EV/EBITDA of 6.03x and a P/S of 0.88x, suggesting that the market is pricing the firm as a commoditized marketing service rather than a high-growth healthcare data analytics platform, despite its unique EHR integration positioning.
The current forward P/E of 5.44x implies that investors are heavily discounting future earnings, likely due to the historical volatility in profitability and the reliance on campaign-based revenue. This valuation gap compared to peers like Doximity suggests that the market requires further evidence of sustained, non-transactional revenue growth before re-rating the stock.
Capital Efficiency Remains Highly Volatile
Based on quarterly filings, ROIC has fluctuated significantly, reaching a peak of 5.1% in 2025Q4 before declining to 0.2% in 2026Q1, indicating that the company has struggled to consistently compound capital while navigating the integration of recent acquisitions and shifting pharmaceutical marketing spend.
The erratic nature of ROIC suggests that the company's core business model is highly sensitive to operational scale and the timing of campaign launches. Investors should monitor whether the shift toward Dynamic Audience Activation can stabilize these returns by reducing the reliance on low-margin, transactional messaging programs.
Working Capital Cycles Impede Liquidity
According to recent SEC filings, the company's DSO has remained elevated, peaking at 160 days in 2026Q1, which highlights significant friction in the collection process and suggests that the firm lacks sufficient leverage over its pharmaceutical clients to accelerate cash conversion cycles.
The lack of consistent DIO and CCC data makes it difficult to assess inventory-like risks, but the high DSO relative to historical norms warrants concern regarding the quality of receivables. This inefficiency in working capital management appears to be a structural drag on the company's ability to self-fund its growth initiatives.
Liquidity Buffers Mask Operational Fragility
As indicated by the 2026Q1 current ratio of 5.37, the company maintains a robust short-term liquidity position, yet this figure appears largely driven by working capital timing rather than a consistent accumulation of cash reserves from core operational activities.
While the current ratio provides a comfortable cushion against immediate obligations, the underlying volatility in net margins suggests that this liquidity could be rapidly depleted during periods of sustained operational underperformance. The company's reliance on EHR partnerships means that any shift in payment terms could quickly impair this seemingly strong liquidity profile.
Misapplication of Traditional Marketing Multiples
The most commonly misapplied metric for OPRX is the P/S ratio, which obscures the company's transition from a transactional messaging provider to a data-driven clinical decision support platform, thereby leading to an undervaluation of its proprietary EHR integration moat.
Analysts often treat OPRX as a commodity marketing firm, but this ignores the high-barrier nature of its point-of-prescribe positioning. A more appropriate framework would involve adjusting for the gross-versus-net revenue reporting of EHR distribution fees to better reflect the true underlying scale and margin potential of the business.